Clinical Trial Update: Two-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome [Phase 3]

View source ↗

Summary

Phase 3 trial of ianalumab (VAY736) in active Sjogren's syndrome completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sjogren Syndrome

Drugs mentioned

• Ianalumab (ianalumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Sjogren Syndrome | Phase 3 | Status: COMPLETED